rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    SRRK
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Scholar Rock at UBS Global Biopharma Conference 2026: early launch gains
      Nov 16Investing.comSRRKUBS
      Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
      Nov 13Yahoo FinanceSRRK
      Scholar Rock (SRRK) Q3 2026 Earnings Call Transcript

      Motley Fool Press Release.

      Nov 10The Globe and MailSRRK
      What Scholar Rock Holding (SRRK)'s ISEMBYLD Launch Means For Shareholders
      Nov 10Yahoo FinanceSRRK
      Scholar Rock Holding Q3 2026 Earnings Call Transcript
      Nov 10BenzingaSRRK
      BioNTech to buy Scholar Rock PRV for $205M (BNTX:NASDAQ)
      Nov 10Seeking AlphaBNTXSRRK
      Scholar Rock earnings beat by $0.03, revenue fell short of estimates
      Nov 10Investing.comSRRK
      Scholar Rock Holding Corporation (SRRK) Reports Q3 Loss, Beats Revenue Estimates
      Nov 10Yahoo FinanceSRRK
      Scholar Rock earnings loom as first Isembyld sales take focus
      Nov 9Investing.comSRRK
      Scholar Rock to Present at Upcoming Investor Conferences
      Nov 3Yahoo FinanceSRRK
      Scholar Rock (SRRK) Stock Could Trade At A Premium On Balance Sheet Hopes

      Scholar Rock Holding has seen its share price move sharply over recent years, which naturally raises a question for anyone looking at the stock today. Is the current US$44.18 price still grounded in the company’s book value, or has the market run ahead of what its balance sheet can reasonably support? Over the past 3 years the stock has returned about 252.3%, which puts a lot of pressure on the underlying book value to justify that kind of gain. The business relies heavily on the strength of...

      Oct 30Yahoo FinanceSRRK
      Tuesday’s insider trading: Scholar Rock director buys $12 million
      Oct 28Investing.comSRRK
      Scholar Rock director Akkaraju buys $12 million in shares
      Oct 28Investing.comSRRK
      Truist reiterates Buy on Scholar Rock stock, cites uptake potential
      Oct 20Investing.comSRRKTFC
      Scholar Rock to Report Third Quarter 2026 Financial Results on November 10, 2026
      Oct 20Yahoo FinanceSRRK
      Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
      Oct 16Yahoo FinanceSRRK
      EMA Resubmission for Apitegromab Might Change The Case For Investing In Scholar Rock Holding (SRRK)
      Oct 16Yahoo FinanceSRRK
      Truist reiterates Buy on Scholar Rock stock, $77 target on launch
      Oct 13Investing.comSRRKTFC
      Analysts Offer Insights on NA Companies: Scholar Rock Holding (SRRK) and Strategy (MSTR)

      Detailed price information for Strategy Inc (MSTR-Q) from The Globe and Mail including charting and trades.

      Oct 10The Globe and MailSRRK
      Raymond James reiterates Scholar Rock stock rating on MAA resubmission
      Oct 8Investing.comSRRK
      Scholar Rock Resubmits Apitegromab Application in EU for Spinal Muscular Atrophy
      Oct 8Yahoo FinanceSRRK
      Scholar Rock resubmits EU application for SMA treatment
      Oct 8Investing.comSRRK
      Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)

      CAMBRIDGE, Mass., October 08, 2026--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology, today announced it has resubmitted the Marketing Authorisation Application (MAA) for apitegromab for the treatment of children and adults with spinal muscular atrophy (SMA) to the European Medicines Agency (EMA).

      Oct 8Yahoo FinanceSRRK
      Scholar Rock Holding Reports Q2 2026 Results: Full Earnings Call Transcript - Scholar Rock Holding (NASDA

      Scholar Rock Holding (NASDAQ:SRRK) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you by Benzinga APIs. For real-time

      Oct 5BenzingaSRRK
      Kuehn Law Encourages Investors of Scholar Rock Holding Corp to Contact Law Firm
      Sep 30MorningstarSRRK
      Weight-loss drug developers line up to tap lucrative market as competition heats up
      Sep 30ReutersSRRKLLYNVO
      Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Scholar Rock Holding (SRRK) and Vertex Pharmaceuticals (VRTX)

      Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

      Sep 26The Globe and MailSRRK
      Scholar Rock added to Wedbush's Best Ideas List
      Sep 25Seeking AlphaSRRK
      Piper Sandler reiterates Scholar Rock stock rating on uptake view
      Sep 25Investing.comSRRK
      Scholar Rock Poised for De-risked Commercial Ramp in Neuromuscular Space, Wedbush Says
      Sep 25Yahoo FinanceSRRK
      Truist Lifts Price Target on Scholar Rock Holding to $77 From $76, Keeps Buy Rating

      Scholar Rock Holding (SRRK) has an average rating of buy and mean price target of $69.12, according

      Sep 24Yahoo FinanceSRRK
      Truist raises Scholar Rock stock price target on drug pricing update
      Sep 24Investing.comSRRK
      Scholar Rock’s Isembyld approval sets up rapid sales ramp
      Sep 23S&P GlobalSRRK
      Weight-loss drug developers line up to tap lucrative market as competition heats up
      Sep 21ReutersSRRKLLYNVO
      JPMorgan raises Scholar Rock stock price target to $70 on launch outlook
      Sep 21Investing.comSRRK
      Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
      Sep 21Yahoo FinanceSRRK
      Scholar Rock Holding (SRRK) Wins FDA Approval for ISEMBYLD. Can Add-On Use Scale?

      Scholar Rock Holding Corporation (NASDAQ:SRRK) secured FDA approval on September 11 for ISEMBYLD, apitegromab-mstn, to treat spinal muscular atrophy in adults and children aged two and older currently receiving survival motor neuron 2 (SMN2)-targeted therapy. Approval opens a commercial opportunity built around adding muscle-directed treatment to existing care. The investment question now shifts to how […]

      Sep 17Yahoo FinanceSRRK
      Scholar Rock (SRRK) Stock Fair Value Edges Higher After Isembyld Approval And Analyst Revisions
      Sep 15Yahoo FinanceSRRK
      Scholar Rock: Reiterating 'Strong Buy' On FDA Approval SMA And Expansions Now In Play

      FDA approval of Scholar Rock’s ISEMBYLD (apitegromab) for SMA drives a Strong Buy case, with $2B+ market upside and EU/JP catalysts. Click for more on SRRK stock.

      Sep 15Seeking AlphaSRRK
      Scholar Rock stock downgraded at Barclays (SRRK:NASDAQ)

      Scholar Rock (SRRK) stock slides as Barclays downgrades the company despite FDA approval of its spinal muscular atrophy drug, Isembyld. Read more here.

      Sep 15Seeking AlphaSRRKBCS
      UBS reiterates Buy on Scholar Rock stock, keeps $60 price target
      Sep 15Investing.comSRRK
      H.C. Wainwright raises Scholar Rock stock price target on FDA approval
      Sep 15Investing.comSRRK
      Barclays downgrades Scholar Rock stock rating on valuation
      Sep 15Investing.comSRRK
      Scholar Rock Faces Early Isembyld Launch Friction From FDA Safety Requirements, Truist Says
      Sep 15Yahoo FinanceSRRK
      Barclays Downgrades Scholar Rock to Equalweight From Overweight, Adjusts PT to $58 From $55

      Scholar Rock Holding (SRRK) has an average rating of buy and mean price target of $69.62, according

      Sep 15Yahoo FinanceSRRK
      Scholar Rock Shares Fall After Barclays Downgrade
      Sep 15Yahoo FinanceSRRK
      Scholar Rock Marks 'Defining Moment' with First Muscle-Targeted Treatment for Spinal Muscular Atrophy

      The U.S. Food and Drug Administration on Friday approved ISEMBYLD (apitegromab-mstn) from Scholar Rock for spinal muscular atrophy (SMA) in adults and pediatric patients aged 2 years and older. The decision makes ISEMBYLD the first muscle-targeted therapy to demonstrate motor...

      Sep 15Yahoo FinanceSRRK
      Scholar Rock says its first muscle-targeted SMA therapy will cost about $310,000 annually
      Sep 14ReutersSRRK
      Scholar Rock Marks 'Defining Moment' with First Muscle-Targeted Treatment for Spinal Muscular Atrophy
      Sep 14BenzingaSRRK
      Scholar Rock Shares Rise 9.1% After FDA Approves ISEMBYLD for Spinal Muscular Atrophy

      Scholar Rock Holding Corp (NASDAQ:SRRK) shares rose 9. 1% in pre-market trading to $60.

      Sep 14Yahoo FinanceSRRK

      This is the newest page. Registered accounts read further back.